SURAKSHA NSE filing

Suraksha Diagnostic Presents Investor Presentation for Q2 & H1 FY27 Results

The RealCase readHigh impact Positive

Suraksha Diagnostic reported a 26% YoY revenue growth in Q2 FY27, with EBITDA margin at 36.7% and PAT margin at 15.1%. For H1 FY27, total income was ₹1,893 million, EBITDA ₹678.5 million, and PAT ₹278.0 million. The company commissioned five new centers and highlighted strong growth in patient and test volumes. An investor presentation for these results was shared on November 12, 2026.

Why it matters

The announcement provides detailed financial results and strategic outlook, which are crucial for investor decision-making and market perception.

The market read

The company reported robust financial performance with significant year-on-year growth in revenue, EBITDA, and PAT, alongside strategic network expansion.

Suraksha Diagnostic Limited has released an investor presentation detailing its financial results for the quarter and half-year ended September 30, 2026 (Q2 & H1 FY27). The presentation was shared with the stock exchanges on November 12, 2026, and will be exhibited during an earnings call scheduled for November 13, 2026, at 11:00 AM IST. The company reported a robust performance in Q2 FY27, with a year-on-year revenue growth of 26%. Ritu Mittal, Joint Managing Director & CEO, highlighted a quarterly EBITDA margin of 36.7% and PAT margin of 15.1%, attributing the success to healthy growth in patient and test volumes. Network expansion also continued, with five new centers commissioned during the quarter. The company remains confident in its growth trajectory for the second half of FY27, focusing on driving performance across the existing network and pursuing disciplined expansion.

For the half-year ended September 30, 2026 (H1 FY27), Suraksha Diagnostic reported total income of ₹1,893 million, EBITDA of ₹678.5 million (36.3% margin), and PAT of ₹278.0 million (14.9% margin). Key operating metrics for H1 FY27 include Revenue per Patient at ₹2,335 and EBITDA per Patient at ₹849, with 4.50 million tests performed and a footfall of 0.80 million patients. The company also noted significant YoY growth in EBITDA (37%) and PAT (54%) for H1 FY27 compared to H1 FY26. The presentation also covers detailed financial performance for Q2 FY27 and H1 FY27, including consolidated profit and loss, balance sheet, and cash flow statements, along with a comparison between IGAAP and Ind AS accounting standards. The company's strategy focuses on expanding its footprint in Eastern and North-Eastern India, leveraging technology, enhancing its one-stop diagnostic model, and strengthening B2B partnerships.

Filing to action

What to do with a filing like this

Suraksha Diagnostic Limited filed this with the NSE as a statutory disclosure, categorised under investor presentation. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.

That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.

See the model portfolios
Primary source

A plain-language summary of a public exchange filing by Suraksha Diagnostic Limited. Read the original for the full detail.

View original filing